- Sign MOU to Collaborate on Process Development and GMP Manufacturing

▲ MOU Signed for Process Development and GMP Manufacturing Collaboration

Hwasun, Jeollanam-do, South Korea — PCMO  announced that it signed a Memorandum of Understanding (MOU) with VIEL-T on July 9 to strengthen collaboration in the development and manufacturing of mRNA therapeutics.

VIEL-T is a biotechnology venture specializing in next-generation RNA therapeutics. Leveraging a proprietary platform technology that directly targets disease-causing RNA, the company is advancing the development of first-in-class RNA therapeutics for a wide range of indications, including infectious diseases, cancer, and autoimmune disorders. Through this partnership, the two organizations will collaborate across the entire mRNA drug development value chain—from process development and GMP manufacturing to commercialization.

Under the agreement, the two organizations will cooperate in the following areas ▲Provision of proprietary mRNA and RNA technologies and related products ▲Research and development process development, GMP manufacturing and commercialization support for mRNA therapeutics ▲Discovery of new pipelines and joint R&D based on proprietary platform technologies ▲Customized technology commercialization support ▲Exchange of industry trends and technical information ▲Shared utilization of facilities and manufacturing equipment

As part of the collaboration, VIEL-T will focus on contract research (CRO) activities, while PCMO will provide GMP-based process development and contract development and manufacturing (CDMO) services. By combining their respective expertise, the two organizations aim to accelerate the development and commercialization of mRNA therapeutics.

Recently, PCMO completed the construction of its mRNA manufacturing facility, establishing an integrated GMP production platform covering the entire manufacturing process from plasmid DNA (pDNA) production to drug product (DP) manufacturing. Building on this infrastructure, PCMO plans to expand support for process development, production of non-clinical and clinical trial materials, process validation, and commercial manufacturing to facilitate the successful development and commercialization of mRNA therapeutics.